…
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alibaba Health Information Technology Limited operates digital healthcare services in China, including online pharmacy retail, health management and technology solutions for hospitals and insurers. It may benefit from China's aging population, rising e-commerce penetration of pharmaceuticals and broader healthcare digitization, and appears positioned to leverage platform capabilities and partnerships to scale services.
Key risks include Chinese regulatory and reimbursement changes affecting internet healthcare, intense competition from other online platforms, execution and governance risks around scaling services, and concentration in the domestic market.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | 1559.97M | 939.40M | 550.99M | -252.51M | 401.22M |
| Minority interest | 0.41M | 0.34M | -0.86M | 0.39M | -20.35M |
| Net income | 1432.43M | 883.48M | 533.41M | -265.56M | 348.59M |
| Selling general administrative | 390.59M | 359.98M | 379.49M | 395.08M | 293.60M |
| Selling and marketing expenses | 2258.37M | 1776.56M | 1768.67M | 1981.28M | 1222.01M |
| Gross profit | 7432.09M | 5895.32M | 5701.33M | 4107.99M | 3617.25M |
| Reconciled depreciation | 57.60M | 53.68M | 63.72M | 60.58M | 39.63M |
| Ebit | 1562.58M | 945.37M | 493.11M | -792.29M | 266.18M |
| Ebitda | 1620.18M | 999.05M | 556.83M | -731.72M | 305.81M |
| Depreciation and amortization | 57.60M | 53.68M | 63.72M | 60.58M | 39.63M |
| Operating income | 1576.06M | 640.18M | 493.11M | -792.29M | 266.18M |
| Other operating expenses | 29022.23M | 26314.29M | 26794.80M | 21596.46M | 15407.64M |
| Interest expense | 2.61M | 5.97M | 5.83M | 3.81M | 2.45M |
| Tax provision | 127.95M | 56.26M | 16.73M | 13.43M | 58.54M |
| Interest income | 464.85M | 478.03M | 331.59M | 209.84M | 165.41M |
| Net interest income | 462.24M | 472.06M | -5.83M | 206.02M | 162.97M |
| Income tax expense | 127.95M | 56.26M | 16.73M | 13.43M | 58.54M |
| Total revenue | 30598.29M | 27026.56M | 26763.02M | 20577.62M | 15518.47M |
| Total operating expenses | 5856.03M | 5183.06M | 5733.12M | 5126.84M | 3506.42M |
| Cost of revenue | 23166.20M | 21131.23M | 21061.68M | 16469.62M | 11901.22M |
| Total other income expense net | -16.09M | 299.22M | 57.89M | 539.78M | 135.04M |
| Net income from continuing ops | 1432.01M | 883.14M | 534.26M | -265.94M | 342.68M |
| Net income applicable to common shares | - | - | - | -265.56M | 348.59M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 21178.42M | 19705.34M | 20747.56M | 19201.97M | 17739.20M |
| Intangible assets | 275.22M | 292.07M | 309.01M | 326.21M | 2.94M |
| Other current assets | 687.73M | 1774.25M | - | 63.12M | 11.02M |
| Total liab | 4865.26M | 5187.73M | 5600.22M | 5129.74M | 3457.60M |
| Total stockholder equity | 16312.18M | 14544.21M | 15173.71M | 14098.42M | 14301.95M |
| Other current liab | 1743.00M | 1551.83M | 1685.96M | 1242.88M | 828.99M |
| Common stock | 142.79M | 142.78M | 119.13M | 119.10M | 118.86M |
| Capital stock | 142.79M | 142.78M | 119.13M | 119.10M | 118.86M |
| Retained earnings | 1324.46M | -11.97M | -841.69M | -1309.01M | -985.65M |
| Other liab | - | - | - | 222.85M | 39.32M |
| Good will | 810.85M | 810.85M | 810.85M | 810.85M | 54.58M |
| Other assets | - | - | - | 37.68M | 17.53M |
| Cash | 2218.30M | 9553.11M | 10917.17M | 10547.85M | 11636.77M |
| Total current liabilities | 4742.17M | 5025.46M | 5437.44M | 4822.13M | 3400.87M |
| Net debt | -2182.78M | -9470.94M | -10839.37M | -10412.44M | -11599.03M |
| Short term debt | 10.58M | 34.19M | 37.44M | 50.66M | 20.33M |
| Short long term debt total | 35.52M | 82.17M | 77.80M | 135.41M | 37.74M |
| Other stockholder equity | 51463.79M | 14413.40M | 15896.26M | 13979.32M | 14183.09M |
| Property plant equipment | - | - | - | 165.11M | 52.29M |
| Total current assets | 12276.18M | 13512.24M | 14913.79M | 13565.51M | 14199.73M |
| Net tangible assets | - | - | - | 12961.35M | 14244.44M |
| Short term investments | 5881.55M | -694.00M | - | - | - |
| Net receivables | 2073.39M | 785.14M | 578.08M | 1073.94M | 772.91M |
| Inventory | 1415.22M | 1399.74M | 2102.31M | 1550.15M | 1468.61M |
| Accounts payable | 2852.38M | 3350.57M | 3714.05M | 3528.60M | 2551.55M |
| Accumulated other comprehensive income | -36618.87M | -36859.38M | - | - | - |
| Non currrent assets other | 93.48M | 86.44M | 4611.52M | 4316.89M | 3429.68M |
| Non current assets total | 8902.24M | 6193.10M | 5833.77M | 5636.46M | 3539.48M |
| Capital lease obligations | 35.52M | 82.17M | 77.80M | 135.41M | 37.74M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -2596.48M | -4880.90M | -532.44M | 2799.35M | -4724.61M |
| Change to liabilities | - | - | 0.00M | 1029.67M | 735.04M |
| Total cashflows from investing activities | -2596.48M | -4880.90M | - | 1872.31M | -4961.48M |
| Net borrowings | - | - | - | -47.01M | -31.62M |
| Total cash from financing activities | -72.52M | -1982.39M | -111.28M | -58.63M | 8922.41M |
| Change to operating activities | - | - | - | -44.39M | -122.06M |
| Net income | 1559.97M | 939.40M | 550.99M | -252.51M | 401.22M |
| Change in cash | -1271.87M | -5746.68M | -104.58M | 2089.15M | 4657.29M |
| Begin period cash flow | 3490.17M | 9236.85M | 9341.43M | 7252.27M | 2594.98M |
| End period cash flow | 2218.30M | 3490.17M | 9236.85M | 9341.43M | 7252.27M |
| Total cash from operating activities | 1395.03M | 1079.83M | 255.69M | 424.36M | 1009.43M |
| Issuance of capital stock | 4.59M | 0.88M | 12.89M | 9.69M | 8993.71M |
| Depreciation | 57.60M | 53.68M | 63.72M | 60.58M | 39.63M |
| Other cashflows from investing activities | -9084.21M | 229.28M | - | -112.09M | -234.53M |
| Change to inventory | -107.88M | 614.10M | -711.69M | -129.20M | -283.83M |
| Change to account receivables | -273.59M | -211.49M | -64.63M | -201.98M | 7.44M |
| Sale purchase of stock | -39.93M | -104.57M | -81.58M | -16.52M | -39.58M |
| Other cashflows from financing activities | 0.92M | -1838.77M | -42.59M | -51.80M | -31.73M |
| Change to netincome | - | - | - | -24.76M | 284.62M |
| Capital expenditures | 18.90M | 22.78M | 5.92M | 15.12M | 17.56M |
| Change in working capital | -567.97M | -337.51M | -568.13M | 671.12M | 294.65M |
| Stock based compensation | 224.53M | 266.06M | 308.89M | 408.10M | 396.96M |
| Other non cash items | 120.90M | 158.21M | -99.78M | -462.92M | -123.03M |
| Free cash flow | 1376.13M | 1057.05M | 249.77M | 409.25M | 991.87M |
Sector: Healthcare Industry: Pharmaceutical Retailers
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALBBY Alibaba Health Information Technology Limited |
- -% |
7.65 | 34.43 | 19.84 | 0.29 | 3.79 | 1.73 | 25.72 |
| JDHIF JD Health International Inc |
- -% |
4.79 | 15.09 | 15.11 | 0.18 | 1.52 | 0.59 | 6.26 |
| RADLY Raia Drogasil SA ADR |
0.09 3.35% |
2.78 | 22.35 | 24.69 | 0.14 | 4.59 | 0.90 | 10.93 |
| ALBHF Alibaba Health Information Technology Limited |
- -% |
0.33 | 17.35 | 16.69 | 0.16 | 2.11 | 0.89 | 13.04 |
| RTEZ Rest EZ Inc. |
- -% |
70.00 | - | - | 385518.44 | 5.92 | - | - |
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
| Name | Title | Year Born |
|---|---|---|
| Mr. Shunyan Zhu | Chairman & CEO | 1971 |
| Mr. Yanwu Tu | CFO & Exec. Director | 1979 |
| Mr. Difan Shen | COO & Exec. Director | 1979 |
| Mr. Chun Chung Kwong | Financial Controller | NA |
| Ms. Chun Ka Yan | Company Sec. | NA |
| Ka Yan Chun | Company Sec. | NA |
| Ms. Zhang Hua | Chief People Officer | NA |
| Mr. Difan Shen | CEO & Executive Director | 1978 |
| Mr. Yanwu Tu | CFO & Executive Director | 1979 |
| Ms. Hiu Leong Tsui | Legal Counsel & Joint Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.